Mohamed Eid is Chief Medical Officer at Verdiva Bio focusing on an investigational portfolio of peptides and drug delivery platforms for obesity and cardiometabolic diseases. He has 30+ years’ experience in senior roles leading clinical research, medical, regulatory and pharmacovigilance programs in the US, Japan, Korea, Canada, and Europe.

Mohamed has been playing a critical role in translating emerging science into innovative medicines by guiding global drug development, multinational clinical trials, and/or regulatory submissions for GLP-1 based therapies (VRB-101, Survodutide, Semaglutide, Liraglutide), Amylin analogs (VRB-103, AM833), novel insulins (insulin degludec, insulin detemir), SGLT-2 inhibitors (Empagliflozin), and other cardiovascular and metabolic medicines.

A physician by training who practiced Endocrine, Diabetes & Metabolism, he holds two master’s degrees majoring in Clinical Research and in Healthcare Administration from the University of Minnesota where he is currently Affiliate Assistant Professor.

In addition to his medical background, Mohamed has been extensively trained in executive management and organizational effectiveness at The University of Oxford Saïd Business School, The Harvard Business School, The Wharton School of Business, and The Carlson School of Management.